Eagle Pharmaceuticals Inc banner

Eagle Pharmaceuticals Inc
NASDAQ:EGRX

Watchlist Manager
Eagle Pharmaceuticals Inc Logo
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Watchlist
Price: 0.25 USD Market Closed
Market Cap: $3.2m

Wall Street
Price Targets

EGRX Price Targets Summary
Eagle Pharmaceuticals Inc

There are no price targets for EGRX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Eagle Pharmaceuticals Inc Competitors:
Price Targets
CYBR
Cyberark Software Ltd
22% Upside
PRQR
ProQR Therapeutics NV
550% Upside
SSRM
SSR Mining Inc
13% Upside

Revenue
Forecast

42% / Year
Past Growth
-10% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
42% / Year
Past Growth
-10% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

For the last 8 years the compound annual growth rate for Eagle Pharmaceuticals Inc's revenue is 42%. The projected CAGR for the next 3 years is -10%.

Operating Income
Forecast

N/A
Past Growth
-21% / Year
Estimated Growth
Estimates Accuracy
-40%
Average Miss
N/A
Past Growth
-21% / Year
Estimated Growth
Estimates Accuracy
-40%
Average Miss

The compound annual growth rate of Eagle Pharmaceuticals Inc's operating income for the next 3 years is -21%.

Net Income
Forecast

N/A
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss
N/A
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss

The compound annual growth rate of Eagle Pharmaceuticals Inc's net income for the next 3 years is 4%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EGRX's stock price target?
Not Available

EGRX doesn't have any price targets made by Wall Street professionals.

What is Eagle Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
-10%

For the last 8 years the compound annual growth rate for Eagle Pharmaceuticals Inc's revenue is 42%. The projected CAGR for the next 3 years is -10%.

What is Eagle Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
-21%

The compound annual growth rate of Eagle Pharmaceuticals Inc's operating income for the next 3 years is -21%.

What is Eagle Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
4%

The compound annual growth rate of Eagle Pharmaceuticals Inc's net income for the next 3 years is 4%.

Back to Top